Physician profile
Walker Lyerly
NPI 1912919267
$1,622.61
in general payments reported to CMS, 2019-2025
14 companies · $507 in 2025
The $507 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $37.63 · 2021: $129 · 2022: $39.24 · 2023: $477 · 2024: $330 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,312.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $253.48 | 2021-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $238.68 | 2022-2025 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $228.35 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $191.01 | 2019-2021 | |
| Corium, LLC | $137.08 | 2023-2025 | Azstarys |
| Abbvie INC. | $117.66 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $105.44 | 2023-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $94.06 | 2020-2024 | Trintellix |
| Vanda Pharmaceuticals INC. | $76.84 | 2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $68.38 | 2023-2024 | Rexulti, Brintellix |
| Bausch Health US, LLC | $36.47 | 2024-2025 | Aplenzin |
| Tris Pharma INC | $32.71 | 2024-2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $25.66 | 2025 | Auvelity |
| Neos Therapeutics, LP | $16.79 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walker Lyerly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.